IMUX
Immunic (IMUX)
$54
About Immunic (IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
Details
Daily high
$14.84
Daily low
$13.86
Price at open
--
52 Week High
$15.84
52 Week Low
$5.06
Market cap
198.1M
Dividend yield
0.00%
Volume
97
Avg. volume
161,567
P/E ratio
-2.41
Immunic News
Details
Daily high
$14.84
Daily low
$13.86
Price at open
--
52 Week High
$15.84
52 Week Low
$5.06
Market cap
198.1M
Dividend yield
0.00%
Volume
97
Avg. volume
161,567
P/E ratio
-2.41